Athyrium Capital Management

What is Athyrium Capital Management?

Athyrium Capital Management is a specialized asset management firm established in 2008 that is dedicated to identifying investment opportunities within the global healthcare sector. As of their latest update, they advise funds that collectively yield over $4.5 billion in committed capital.

Athyrium’s approach encompasses a broad spectrum of financial instruments, which include royalties, structured credit, equities, and select special situations.

With a mandate to invest in healthcare-focused assets, their portfolio is diverse, extending across various subsectors such as pharmaceuticals, biologics, biotechnology, specialty and generic pharmaceuticals, medical devices and products, laboratory diagnostics, healthcare services, and information technology.

Their comprehensive investment experience within the healthcare sphere is reflected in the diverse asset classes they engage with: public equity, private equity, fixed income, royalties, and other structured securities. Athyrium purposefully seeks out assets across a wide array of healthcare verticals, ranging from drug development to medical technology and healthcare provision.

These investments typically align with their sizeable investment range; they cater to significant capital injections with a minimum and maximum investment size of $650 million, representing a consistent investment strategy that targets substantial and mature healthcare enterprises.

Given this investment profile, Athyrium aims to foster growth and innovation within the healthcare industry by providing ample financial resources to established companies in need of substantial capital to scale their operations, enhance their product offerings, or expand their market reach.